This risk minimisation material is a condition of the marketing authorisation. It contains important safety information that you need to be aware of before, during and after treatment with ipilimumab. Please ensure that you carry this card with you at all times to inform any healthcare professional treating you (e.g., emergency department personnel) that you are receiving treatment with ipilimumab.